Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Tykerb Effective In Herceptin Failures; CNS Relapse Rate, CV Safety Touted

  • News

Executive Summary

GlaxoSmithKline's Tykerb (lapatinib) should replace Genentech's Herceptin (trastuzumab) as the standard of care for trastuzumab-refractory breast cancer patients, GSK Senior VP-Oncology Medicine Development Center Paolo Paoletti said June 3

You may also be interested in...



GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer

GlaxoSmithKline is pricing its breast cancer therapy Tykerb at a slight discount to Genentech's Herceptin (trastuzumab) in the metastatic breast cancer setting

GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer

GlaxoSmithKline is pricing its breast cancer therapy Tykerb at a slight discount to Genentech's Herceptin (trastuzumab) in the metastatic breast cancer setting

Genentech Herceptin Detailing Will Work To Limit Tykerb To Salvage Patients

Genentech's counterdetailing efforts for Herceptin will focus on limiting use of GlaxoSmithKline's Tykerb to refractory advanced and metastatic breast cancer patients, Genentech BioOncology VP-Sales and Marketing John Orwin said Nov. 16

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Recent And Upcoming FDA Advisory Committee Meetings

Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier

US FDA’s PDUFA VIII Ideas Could Include Creating Regulatory Science Research Program

Medicare Part B Inflation Rebate List Doubles For Third Quarter, Adds Several Amgen Drugs

See All
UsernamePublicRestriction

Register

PS047284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By